Core Insights - Junpu Intelligent (stock code: 688306.SH) reported significant growth in new orders and gross margin in Q3 2025, focusing on core business and strategic emerging industries [1][2] - The company achieved a total of 1.881 billion yuan in new orders for the first three quarters, a year-on-year increase of 37.32%, with a gross margin of 20.29%, up 1.06 percentage points from the previous year [1][2] Business Expansion and Order Acquisition - In the first three quarters, Junpu Intelligent secured new orders totaling 1.881 billion yuan across various sectors, including healthcare, high-end consumer goods, and new energy vehicles, with a backlog of 3.738 billion yuan [2] - Notable projects include high-precision insulin pen marking for a leading domestic pharmaceutical company and assembly testing for HIV detection products for a major medical device firm [2] - The company also received orders for assembly testing from a German high-end kitchen appliance brand and a well-known American razor manufacturer, as well as production line orders for a global leading parts company in the new energy vehicle sector [2] Strategic Emerging Industry Layout - Junpu Intelligent has developed a comprehensive technology capability for embodied intelligent robots, enabling self-controlled research and production from humanoid robot development to complete machine production [3] - The company launched its first production line at Ningbo Puzhi Future Robot Co., achieving an annual capacity increase from 1,000 to over 3,000 units, with over 200 robots already produced [3] - A government-supported innovation center for embodied intelligent robots has been established to promote technology research, scene testing, and industrial collaboration [3] Research and Development Investment - In Q3 2025, Junpu Intelligent's R&D investment increased significantly by 70.32%, totaling 49.1122 million yuan for the first three quarters [7] - The company is focusing on AI and embodied intelligent robots in industrial applications, aiming to become a leader in "AI + automation" [7] - The chairman explained that revenue fluctuations are primarily due to project execution cycles, with major projects impacting quarterly revenue [7]

宁波均普智能制造股份有限公司 2025年第五次临时股东会会议资料 证券代码：688306 证券简称：均普智能 | 19 | | --- | 宁波均普智能制造股份有限公司 2025年第五次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《宁波均普智能制造股份有限公司章程》(以下简称" 《公司章程》")《宁波均普智能制造股份有限公司股东会议事规则》等相关规 定，宁波均普智能制造股份有限公司(以下简称"公司")特制定2025年第五次临 时股东会会议须知： 一、公司股东、股东代理人及其他出席者可以采用网络投票方式参加本次股 东会。需参加现场会议的股东、股东代理人及其他出席者应当听从公司工作人员 安排，并配合现场要求，接受身份核对等相关工作。 二、为保证本次会议的严肃性和正常秩序，切实维护与会股东及股东代理人 的合法权益，除出席会议的股东及股东代理人、公司董事、见证律师、董事会邀 请的人员以及列席会议的高级管理人员外，公司有权依法拒绝其他无关人员进入 会场。 三、出席会议的股东及股东代理 ...

1、 宁波具身智能机器人创新中心启用 均普智能与智元机器人共同建设的宁波具身智能机器人创新中心正式启用。具体来看，该创新中心聚焦工 业制造领域的实景数据采集、机器人软硬件二次开发、测试认证与商业化应用，依托均胜集团全球各地的 工厂场景资源、制造经验与客户生态，打通"技术-产能-场景"全链条，推动具身智能机器人规模化落地， 为制造业智能化升级提供解决方案。均胜集团副总裁、均普机器人研究院与普智机器人董事长周兴宥表 示:"机器人通用本体与工业场景之间的'最后一公里'鸿沟，是行业规模化落地的最大阻碍。"而解决这一痛 点，恰恰是均普智能的核心优势所在。 2、 松延动力创始人姜哲源称价格下探将成行业趋势 5、 IDC预测2029年全球机器人市场规模将突破4,000亿美元 近日，松延动力正式宣布，将于近期发布全球首款定价在万元以内的高性能人形机器人"Bumi小布米"。松 延动力创始人、董事长姜哲源在接受媒体采访时表示，该款机器人定价万元以内的核心目的，是通过价格 下探触达更多人群、涌现新场景，这是更有价值的方向。"价格下探将成为人形机器人行业的未来趋势， 未来所有人形机器人公司都会下调价格，最终收敛到合理利润率、合理价格 ...

每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ （记者 王晓波） 每经AI快讯，均普智能（SH 688306，收盘价：12.75元）10月24日晚间发布三季度业绩公告称，2025年 前三季度营收约15.08亿元，同比减少4.09%；归属于上市公司股东的净利润亏损约5434万元；基本每股 收益亏损0.0447元。 截至发稿，均普智能市值为157亿元。 ...

Financial Performance - The company's revenue for Q3 2025 was ¥476,230,487.51, representing a year-on-year increase of 5.23%[3] - The total profit for the period was -¥41,123,724.11, a decrease of 39.60% compared to the same period last year[3] - The net profit attributable to shareholders was -¥26,570,674.77, down 44.63% year-on-year[3] - Total revenue for the first three quarters of 2025 was CNY 1,508,335,126.07, a decrease of 4.1% compared to CNY 1,572,717,927.33 in the same period of 2024[23] - The net profit for the first three quarters of 2025 was a loss of CNY 54,481,690.74, compared to a loss of CNY 51,301,902.38 in the same period of 2024, indicating a worsening of 4.3%[24] Profitability and Margins - The gross profit margin for the first three quarters of 2025 improved to 20.29%, an increase of 1.06 percentage points from the full year of 2024[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses showed a significant improvement, with a reduction in losses of ¥9,586,200.00, a year-on-year increase of 13.95%[5] - Total profit for the reporting period decreased by 39.60%, resulting in a loss of 11.67 million yuan due to restructuring costs of 24.85 million yuan[10] - Net profit attributable to shareholders decreased by 44.63%, with an increase in loss attributed to additional restructuring costs[10] Research and Development - Research and development expenses totaled ¥21,490,691.86 for the quarter, a significant increase of 70.32% year-on-year[4] - Research and development expenses increased to CNY 45,985,638.13 in 2025 from CNY 44,725,767.76 in 2024, representing a growth of 2.8%[24] - Research and development expenses increased by 70.32% due to periodic impacts of project expenditures[10] Cash Flow and Liquidity - The net cash flow from operating activities for the first three quarters was ¥8,285,375.42, a decrease of 84.73% year-on-year[3] - Cash inflow from operating activities for the first three quarters of 2025 was approximately $1.79 billion, a decrease of 7.0% compared to $1.93 billion in the same period of 2024[28] - Net cash flow from operating activities was $8.29 million, significantly down from $54.26 million in the first three quarters of 2024, reflecting a decline of 84.7%[29] - Cash inflow from investment activities decreased to approximately $423.62 million in 2025 from $1.03 billion in 2024, a drop of 58.8%[29] - Cash inflow from financing activities increased to approximately $991.00 million in 2025 from $485.93 million in 2024, marking a growth of 104.1%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,195,592,262.72, reflecting an increase of 11.15% from the end of the previous year[4] - Total liabilities increased to CNY 3,386,185,439.57 from CNY 2,917,006,738.21, reflecting a rise of 16.1%[21] - The company's goodwill rose to CNY 723,155,146.56 from CNY 652,930,017.22, an increase of 10.8%[20] Orders and Market Expansion - The company signed multiple significant orders in Q3 2025, including a high-precision insulin pen project for a leading domestic pharmaceutical company, with production capacity reaching 80 units per minute[16] - Total new orders for the first three quarters of 2025 amounted to 1.881 billion RMB, with a backlog of 3.738 billion RMB[16] - The company is actively expanding its market presence in the medical and automotive sectors, securing contracts with leading global companies[16] Inventory and Prepayments - Prepayments increased by 186.42% due to higher advance payments to suppliers, with some projects not yet reaching acceptance milestones[11] - The company reported a significant increase in prepayments, rising to approximately 116.83 million RMB from 40.79 million RMB year-over-year[19] - Inventory increased significantly to approximately 2.030 billion RMB from 1.618 billion RMB year-over-year[19] Other Income and Expenses - Other income for the reporting period increased by 1,398.22%, primarily from government subsidies received amounting to 20 million yuan[12] - Investment income for the reporting period decreased by 91.77% due to reduced bank wealth management purchases and lower yields on financial products[12] - Credit impairment losses for the reporting period increased by 552.71% due to an increase in accounts receivable balances[12]

均普智能公告，第三季度营收为4.76亿元，同比增长5.23%；净利润亏损2657.07万元，下降44.63%。前 三季度营收为15.08亿元，同比下降4.09%；净利润亏损5433.77万元，同比下降11.42%。 ...

Core Insights - Ningbo Junpu Intelligent Manufacturing Co., Ltd. has officially launched the Ningbo Embodied Intelligent Robot Innovation Center, marking a significant breakthrough in transitioning humanoid robots from laboratory settings to production lines [2][3] - The innovation center focuses on secondary development and scenario empowerment, aiming to create a closed-loop ecosystem of "technology-capacity-scenario" to support the intelligent upgrade of Ningbo's manufacturing industry [2][3] Company Developments - The innovation center is designed around the global manufacturing scenarios of Yunsen Group and the customer ecosystem of Junpu Intelligent, optimizing robots for specific industrial needs such as precision assembly of automotive parts and flexible operations in high-end consumer goods production [2][3] - Junpu Intelligent has established a comprehensive autonomous technology system for embodied intelligent robots, enabling full control from core technology research to mass production delivery, facilitating the transition of embodied intelligence from laboratory prototypes to large-scale industrial applications [3] Industry Impact - The launch of the innovation center is not only a pivotal moment for Junpu Intelligent but also aims to drive the intelligent upgrade of Ningbo's manufacturing sector through technology output and scenario empowerment [3] - Yunsen Group's Vice President expressed commitment to increasing R&D investment to integrate embodied intelligent technology with more industrial scenarios, positioning robots as standardized equipment for new productivity in the manufacturing sector [3]

均普智能与智元机器人共同建设的宁波具身智能机器人创新中心正式启用。具体来看，该创新中心聚焦 工业制造领域的实景数据采集、机器人软硬件二次开发、测试认证与商业化应用，依托均胜集团全球各 地的工厂场景资源、制造经验与客户生态，打通"技术-产能-场景"全链条，推动具身智能机器人规模化 落地，为制造业智能化升级提供解决方案。 ...

Core Viewpoint - Junpu Intelligent has announced a private placement plan to raise up to 1.161 billion yuan, with nearly half of the funds allocated for the research and industrialization of intelligent robots, amid ongoing financial struggles and project delays since its IPO in 2022 [1][2][3] Group 1: Financing and Project Delays - The company has experienced continuous net profit losses for two and a half years, leading to this new financing initiative [1] - The two core projects from the IPO have faced significant delays, with completion dates pushed from March 2025 to March and September 2026 [2][3] - Regulatory scrutiny has increased due to the company's failure to timely disclose project delays and other financial discrepancies [3] Group 2: Financial Performance - In the first half of 2025, the company reported a revenue of 1.032 billion yuan, a year-on-year decrease of 7.86%, and a net loss of 27.77 million yuan [3] - The company's cumulative net profit, excluding non-recurring gains and losses, has been negative since its listing, totaling a loss of 270 million yuan from 2022 to mid-2025 [3] - Cash flow from operating activities has significantly declined, dropping 84.64% from 197 million yuan in the first half of 2024 to 30.27 million yuan in the same period of 2025, indicating insufficient cash generation from core operations [3] Group 3: Market Performance - Despite poor fundamentals, Junpu Intelligent's stock has performed well in the secondary market, reaching a new high of 16.27 yuan per share on September 18, 2025, with an annual increase of over 60% [4] - As of October 21, 2025, the stock price was 12.73 yuan, representing a cumulative increase of approximately 150% since its listing, which contrasts sharply with its ongoing losses [4] - The company's market valuation has significantly exceeded the industry average, with a total market capitalization of 15.6 billion yuan, reflecting a very high price-to-earnings ratio due to its loss-making status [4]

星标 ★ IPO日报 精彩文章第一时间推送 这家科创板公司正全力押注智能机器人第二增长曲线。 近期，宁波均普智能制造股份有限公司（688306.SH，下称"均普智能"）披露定增预案，拟向不超过35名特定投资者募资不超过11.61亿 元，加码智能机器人研发及产业化项目。 11.61亿投向四大领域 据悉，均普智能成立于2017年1月10日，是一家专注于智能制造装备及数字化软件服务的全球化供应商，主要为汽车工业、消费品、医疗 健康等领域的全球知名制造商提供定制化装配与检测智能制造整体解决方案。 就业绩来看，近年来公司营收规模增速较快，2022年至2024年，实现营业收入分别为19.95亿元、20.96亿元及26.62亿元。不过同期扣 非归母净利润存在较大波动，分别为0.42亿元、-2.06亿元及0.08亿元。 根据公告，本次定增募资扣除发行费用后，将主要用于四大方向，分别为智能机器人研发及产业化项目、医疗健康智能设备全球能力提升 项目、信息化建设项目及补充流动资金项目。 其中，智能机器人研发及产业化项目总投资6.23亿元，拟投入募集资金5.5亿元，建设期36个月，实施地点位于宁波市；医疗健康智能设备 全球能力提升项 ...